Anti-VEGF refers to the use of drugs to inhibit the biosynthesis of VEGF, or the use of antibodies to inhibit the biological function of VEGF. 1. The Chinese name of VEGF is vascular endothelial growth factor, which can act efficiently on vascular endothelial cells, causing proliferation and migration of vascular endothelium, participating in the composition of newborn capillaries, and increasing vascular permeability. It plays a very important role in tumorigenesis and macular degeneration and diabetic retinopathy in the elderly. 2. Anti-VEGF drugs include bevacizumab, ranibizumab, abciximab, compeximab, and ramorubicin. 3. Ranibizumab is a monoclonal antibody that binds to VEGFR2 target and is used in the treatment of gastric cancer and non-small cell lung cancer. Ranibizumab can tightly bind to vascular endothelial growth factor-A and inhibit the proliferation and migration of vascular endothelium, and is used in the treatment of age-related macular degeneration and diabetic macular edema. Anti-VEGF drugs need to be used under the guidance of a professional doctor, patients are prohibited from purchasing their own drugs.